Obesity

Latest News
December 20th 2024

Dr Yehuda Handelsman on How DCRM 2.0 Guidelines Refine CRM Disease Management

December 20th 2024

Contributor: Treating Obesity by Breaking the GLP-1 Pattern

December 17th 2024

Top 5 Most-Read Obesity Articles in 2024

December 13th 2024

Obesity Prevalence, BMI Decreased in US for First Time in a Decade

December 5th 2024

Tirzepatide Outperforms Semaglutide in Weight Loss Trial

Video Interviews
View All
August 2nd 2024

GLP-1 Agonists and the Gut-Brain Axis: A New Era in Obesity Management

January 17th 2024

Dr Ian Neeland Explores Semaglutide Alternatives and Strategies in Cases of Nonresponse

January 15th 2024

Jeff McIntyre Raises NASH Awareness Among Health Care Community

January 15th 2024

Dr Ian Neeland Discusses Uptick in Patients Seeking Semaglutide for Weight Loss

January 10th 2024

Dr Ian Neeland Explains Why Semaglutide Shortage Impacts Injectable and Not Oral Version

January 7th 2024

Dr Ian Neeland on Oral Semaglutide as a Backup Amid Injection Shortage

January 3rd 2024

Dr Ian Neeland Describes Patient Experience During Semaglutide Shortage

December 20th 2023

Dr Peter Katzmarzyk Addresses Social Determinants of Obesity, Proposes Collaborative Support

More News

Semaglutide injection | Image credit: alones - stock.adobe.com
December 5th 2024

Proposal for Medicaid, Medicare Coverage of Obesity Drugs Could Prove Difficult

Julia Bonavitacola
A proposal from the Biden administration to provide coverage of weight loss drugs through Medicaid and Medicare may cost more than it saves.
Medicare enrollment model | image credit: Vitalii Vodolazskyi - stock.adobe.com
November 26th 2024

New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Kyle Munz
If made official, the proposed rule would give Part D and Medicaid beneficiaries expanded coverage to antiobesity drugs starting in 2026.
GLP1 injector pen | Image Credit: © alones-srock.adobe.com
November 25th 2024

FDA Advised to Update Labels on GLP-1 Weight-Loss Drugs

Maggie L. Shaw
In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight loss, with their safety and efficacy primary outcomes of interest.
Semaglutide injectors. | Image Credit :Andreas Prott- stock.adobe.com
November 21st 2024

Semaglutide Eligibility Expands to Over Half of US Adults

Cameron Santoro
Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Obesity | Image credit: MP Studio – stock.adobe.com
November 18th 2024

Overweight, Obesity to Affect 64% of Americans by 2050

Hayden E. Klein
Forecasts indicate a drastic increase in US obesity rates in the next 25 years, emphasizing the need for comprehensive public health strategies.
Vitamin D | Image Credit: © Pixelbliss-stock.adobe.com
November 12th 2024

High-Dose Vitamin D Shows Limited Added Benefits in Hypertension

Maggie L. Shaw
Two doses of vitamin D were investigated for their potential to have a positive impact on systolic and diastolic blood pressures when administered in conjunction with calcium.
Semaglutide Ozempic injection blood sugar obesity - myskin - stock.adobe.com.jpeg
November 6th 2024

Semaglutide Linked to Reduced Health Care Expenses for Patients With Obesity, HF, ASCVD

Giuliana Grossi
Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began semaglutide treatment.
Female adult using a smartphone | Image Credit: Farknot Architect - stock.adobe.com
November 4th 2024

Digital Intervention Reduces Early Childhood Obesity Risk in Diverse Populations

Brooke McCormick
Combining a digital intervention with health behavior counseling improved weight trajectories and lowered obesity risk in racially and ethnically diverse children over 24 months.
Medicaid Budget | Image Credit: zimmytws - stock.adobe.com
October 24th 2024

Medicaid Budget Survey Highlights Postpandemic Challenges and Priorities

Cameron Santoro
The Medicaid budget survey for fiscal years 2024 and 2025 revealed state predictions are expecting a decline in Medicaid enrollment and an increase in spending next year due to the end of pandemic-era policies and federal funding.
Childhood obesity | Image credit: Protsenko Dmitriy - stock.adobe.com
October 24th 2024

How to Address, Prevent Childhood Obesity in the US

Julia Bonavitacola
Establishing habits in children can help to prevent childhood obesity, a rising problem in the US.
Robert Lustig, MD, MSL
October 23rd 2024

How Sugar, Ultraprocessed Foods Are Shaping the Health of America's Youth

Hayden E. Klein
Robert Lustig, MD, MSL, warns that sugary baby foods, rising birth weights, and ultraprocessed school meals are fueling long-term health risks in children.
Semaglutide | Image Credit: Corona Borealis - stock.adobe.com
September 24th 2024

Semaglutide Improves Hidradenitis Suppurativa in Patients With Obesity

Cameron Santoro
Semaglutide treatment significantly improved quality of life and reduced flare-ups in patients with obesity and hidradenitis suppurativa.
Senate. | Image Credit: Corgarashu - stock.adobe.com
September 24th 2024

Semaglutide Accessibility and Affordability Addressed at Senate Committee Hearing

Cameron Santoro
The Senate HELP Committee held a hearing to address the high cost of semaglutide drugs, finding that many patients cannot afford them despite their potential benefits.
Syringe, pills, and measuring tape | Image credit: adragan – stock.adobe.com
September 20th 2024

5 Things Americans Should Know About Weight Loss Drugs

Hayden E. Klein
Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, and their potential downsides is key to making informed decisions.
Blood pressure | Image credit: CasanoWa Stutio - stock.adobe.com
September 5th 2024

Weight Loss Surgery Associated With Blood Pressure Control

Julia Bonavitacola
Patients who had weight-loss surgery were more likely to have managed their high blood pressure compared with those who used medications and modes of management.
Cleveland, OH Image credit: SeanPavonePhoto – stock.adobe.com
August 16th 2024

How Can We Improve Obesity Care in 2024 and Beyond?

Hayden E. Klein
At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care®, experts discussed efforts to implement obesity management science into practice.
Wegovy injections | Image credit: K KStock – stock.adobe.com
August 6th 2024

Rising Costs Lead Insurers to Drop Weight Loss Drug Coverage, Further Increasing Patient Burden

Hayden E. Klein
The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still struggling to meet their goals.
AJMC
August 5th 2024

Inadequate Insurance Coverage for Overweight/Obesity Management

Eden Miller, DO Steve Edelman, MD Carlos Campos, MD, PA John E. Anderson, MD Christopher G. Parkin, MS William H. Polonsky, PhD, CDCES
This article reviews the obesity epidemic in America and discusses inadequate insurance coverage.
AJMC
July 29th 2024

An Efficient Approach to Expand Equitable Access to Antiobesity Medications: Deprescribing After Weight Loss Plateau

David D. Kim, PhD A. Mark Fendrick, MD
The authors advocate for a consideration of 2 distinct phases of obesity management (ie, active weight loss and maintenance of weight loss) to allow substantially more people access to antiobesity medications.
Semaglutide Ozempic injection blood sugar obesity | Image Credit: © myskin - stock.adobe.com
March 6th 2024

Can Different Pricing Models Address the Obesity Problem in America?

Julia Bonavitacola
Getting weight loss drugs into the hands of those who need them could be a matter of changing pricing models to give more patients access to the medication they need.
Woman breastfeeding | Image credit: bernardbodo – stock.adobe.com
January 17th 2024

Early Breastfeeding May Reduce Baby’s Risk of Childhood Obesity

Hayden E. Klein
Breastfeeding infants during the first 3 months can lower their risk of childhood obesity, regardless of the mother's body mass index before pregnancy.
Bariatric surgery | Image credit: Olivier Le Moal – stock.adobe.com
January 15th 2024

Study Reveals How the ACA Impacted Roux-en-Y Gastric Bypass Utilization

Hayden E. Klein
Despite there being more patients undergoing bariatric surgery since the Affordable Care Act (ACA) was enacted in 2010, these surgeries had better postoperative outcomes.
what we're reading logo
January 8th 2024

What We’re Reading: Mask Mandates Return; Sugary Drink Sales Decline; WIC Program Problems

AJMC Staff
COVID-19 subvariant JN.1 accounts for about 62% of US cases, resulting in mask mandates being reinstated in cities across the United States; sugary drink sales fell dramatically across 5 US cities after implementing taxes on them; it is difficult for Special Supplement Nutrition Program for Women and Children (WIC) participants to find approved items.
Ozempic injection | Image credit: mbruxelle – stock.adobe.com
December 21st 2023

An Ongoing Crisis: Semaglutide Shortage Raises Dual Concerns for Obesity and Diabetes Treatment

Hayden E. Klein
An in-depth look into what the drug is being used for and what has contributed to the shortage.
obese woman talking to doctor | Image credit: Studio Romantic - stock.adobe.com
December 19th 2023

Obesity, Women’s Health, Health Equity Among Top Benefit Focuses for Employers in 2024

Skylar Jeremias
A new survey from the National Alliance of Healthcare Purchaser Coalitions found that employers are planning to place a larger focus on obesity management, women’s health, and health equity in 2024 and beyond.
what we're rading logo
December 13th 2023

What We’re Reading: Childhood Obesity Counseling; Humana Lawsuit; AI Use Concern

AJMC Staff
The US Preventive Services Task Force (USPSTF) recommended that children with obesity receive intensive counseling at age 6 to promote healthy diet and exercise habits; a new survey found that the majority of American patients are wary of their doctors using artificial intelligence (AI); a class-action lawsuit was filed Tuesday against health insurer Humana for using an AI algorithm that systemically denies seniors rehabilitation care recommended by their doctors.
What We’re Reading: House Passes Controversial Health Care Package; Insurers Tighten Ozempic Coverage; Arizona Court to Hear Arguments on Near-Total Abortion Ban
December 12th 2023

What We’re Reading: House Passes Health Care Package; Insurers Tighten Ozempic Coverage; Arizona Court to Hear Abortion Arguments

AJMC Staff
End-of-year victory for lawmakers as health care policies pass in the House; insurance limitations prompt concerns over access to semaglutide (Ozempic) for diabetes; a legal battle ensues over the fate of abortion laws in Arizona.
what we're reading logo
December 6th 2023

What We’re Reading: Weight Loss Drug Adherence; Free Birth Control Access; Organ Transplant Test Access

AJMC Staff
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Hydrocodone Pills and Prescription - Andy Dean - stock.adobe.com
December 5th 2023

Obesity Advocates Challenge FDA Over Drug Approval Process Disparities

Giuliana Grossi
The Obesity Action Coalition and other organizations are urging the FDA to address critical gaps in drug testing, emphasizing the need for specific testing in individuals with obesity to ensure safety and efficacy, as current practices expose this population to unnecessary risks.
What We’re Reading: Nursing Homes Without COVID-19 Boosters; Racial Discrimination in Health Care; New Obesity Treatment Hits Market
December 5th 2023

What We’re Reading: Low Rates of COVID-19 Boosters in Nursing Homes; Racial Discrimination in Health Care; New Obesity Treatment

AJMC Staff
Low vaccination rates raise fears of COVID-19 resurgence; a survey highlights racial discrimination in health care; Eli Lilly’s tirzepatide (Zepbound) has entered US pharmacies.
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo